Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NMPA Approval

Dalteparin Sodium Injection

Approval Number

国药准字HJ20170044

CompanyPfizer NV/SA

Registration Date

July 1, 2021

Previous Approval Numbers

H20170044

Drug Information

Generic Name

达肝素钠注射液

Trade Name

法安明

Dosage Form

注射剂

Strength

0.3ml:7500IU

Drug Type

化学药品

Registration Date

July 1, 2021

Expiry Date

June 30, 2026

Company Information

Applicant Company

Company NamePfizer NV/SA

Company Address

Boulevard de la Plaine 17, 1050 Bruxelles, Belgium

Manufacturing Company

Company NamePfizer Manufacturing Belgium

Company Address

Rijksweg 12, 2870 Puurs-Sint-Amands, Belgium

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy